Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Abstract Introduction Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Adis, Springer Healthcare 2025-09-01
Saila:	Dermatology and Therapy
Gaiak:	Abrocitinib Allergic rhinitis Asthma Comorbidity Dupilumab Food allergy
Sarrera elektronikoa:	https://doi.org/10.1007/s13555-025-01516-w
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!